<DOC>
	<DOCNO>NCT02180204</DOCNO>
	<brief_summary>This double-blind parallel arm randomize trial aim assess efficacy safety intravenous Tenecteplase compare intravenous Alteplase eligible patient present symptom acute ischemic stroke within 3 4.5 hour onset .</brief_summary>
	<brief_title>Tenecteplase Versus Alteplase Ischemic Stroke Management ( TALISMAN )</brief_title>
	<detailed_description>Patients present symptom acute ischemic stroke ( AIS ) present within 3 4.5 hour symptom onset meet inclusion criterion intravenous ( IV ) thrombolysis receive , randomize , double-blind fashion , either IV Alteplase 0.9 mg/kg per standard protocol IV Tenecteplase 0.25 mg/kg saline infusion one hour . Patients must also exclusion criterion IV thrombolysis within 3 4.5 hour window . The required imaging non-contrasted CT head . Patients monitor accord standard post-thrombolytic care . A CT head perform 24 hour base standard protocol neurological change . Neurological function 24 hour use NIHSS 3 month base modify mRS NIHSS .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<criteria>1 . Age 18 80 year 2 . Acute neurologic deficit NIHSS ≥ 4 3 . Nonenhanced computed tomography ( NECT ) head show hemorrhage 4 . Acute ischemic stroke symptom onset , time last know well , clearly define 3 4.5 hour 5 . Treatment initiate within 3 4.5 hour symptom onset 1 . Evidence intracranial hemorrhage NECT 2 . Clinical suspicion subarachnoid hemorrhage even normal NECT 3 . NECT show hypodensity great 1/3 cerebral hemisphere ) 4 . History intracranial hemorrhage/stroke 5 . Uncontrolled HTN : At time treatment begin SBP remain &gt; 185 mmHg DBP remain &gt; 110 mmHg despite repeat measurement 6 . Known arteriovenous malformation , neoplasm , aneurysm 7 . Witnessed seizure stroke onset 8 . Acute bleed tendency 9 . Platelet count &lt; 100,000/mm3 10 . Heparin receive prior 48 hour elevate aPTT 11 . Current use anticoagulant ( Coumadin/Warfarin ) irrespective INR 12 . Prior use ( within 48 hour ) direct thrombin inhibitor ( dabigatran ) direct factor Xa inhibitor ( rivaroxaban , apixaban ) 13 . Within prior 3 month : intracranial spinal surgery , head trauma , previous stroke 14 . Arterial puncture noncompressible site within last 7 day 15 . Woman child bear age positive pregnancy test 16 . NIH stroke scale &gt; 25 ( severe deficit ) &lt; 4 dysphasia ( mild deficit ) rapidly improve 17 . Symptoms spontaneously clear 18 . 14 day postoperative post major trauma 19 . Recent gastrointestinal urinary tract hemorrhage within past 21 day 20 . Recent acute MI within past 3 month 21 . Serum glucose &lt; 50 mg/dl &gt; 400 mg/dL 22 . Age &gt; 80 less 18 23 . History ischemic stroke AND diabetes mellitus 24 . Unable obtain consent patient power attorney 25 . Baseline mRS &gt; 2 26 . Consent obtain 20 minute prior closure therapeutic window . 27 . The subject treat thrombolytic agent within past 72 hour 28 . The subject pregnant woman ( positive serum βHCG pregnancy test , positive urine pregnancy test clinically evident pregnancy ) 29 . The subject , opinion investigator , unlikely comply clinical study protocol unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Cerebral Infarction</keyword>
	<keyword>Ischemic Stroke</keyword>
	<keyword>Thrombolysis</keyword>
</DOC>